Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity☆
To access this article, please choose from the options below
☆ Part of this study has been presented at the 10th World Conference on Lung Cancer, 10–14 August 2003, Vancouver, Canada.
PII: S0169-5002(04)00258-2
doi:10.1016/j.lungcan.2004.05.014
© 2004 Elsevier Ireland Ltd. All rights reserved.
